Candida glabrata: Difference between revisions

Jump to navigation Jump to search
WikiBot (talk | contribs)
m Changes made per Mahshid's request
 
Line 33: Line 33:
[[Category:Ascomycota]]
[[Category:Ascomycota]]
[[Category:Yeasts]]
[[Category:Yeasts]]
[[Category:Infectious disease]]
 


[[fr:Candida glabrata]]
[[fr:Candida glabrata]]

Latest revision as of 17:18, 18 September 2017

Candida glabrata
File:Glabrata.jpg
Scientific classification
Kingdom: Fungi
Phylum: Ascomycota
Subphylum: Saccharomycotina
Class: Saccharomycetes
Order: Saccharomycetales
Family: Saccharomycetaceae
Genus: Candida
Species: C. glabrata
Binomial name
Candida glabrata
(Anderson) Meyer & Yarrow
Synonyms

Torulopsis glabrata

WikiDoc Resources for Candida glabrata

Articles

Most recent articles on Candida glabrata

Most cited articles on Candida glabrata

Review articles on Candida glabrata

Articles on Candida glabrata in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Candida glabrata

Images of Candida glabrata

Photos of Candida glabrata

Podcasts & MP3s on Candida glabrata

Videos on Candida glabrata

Evidence Based Medicine

Cochrane Collaboration on Candida glabrata

Bandolier on Candida glabrata

TRIP on Candida glabrata

Clinical Trials

Ongoing Trials on Candida glabrata at Clinical Trials.gov

Trial results on Candida glabrata

Clinical Trials on Candida glabrata at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Candida glabrata

NICE Guidance on Candida glabrata

NHS PRODIGY Guidance

FDA on Candida glabrata

CDC on Candida glabrata

Books

Books on Candida glabrata

News

Candida glabrata in the news

Be alerted to news on Candida glabrata

News trends on Candida glabrata

Commentary

Blogs on Candida glabrata

Definitions

Definitions of Candida glabrata

Patient Resources / Community

Patient resources on Candida glabrata

Discussion groups on Candida glabrata

Patient Handouts on Candida glabrata

Directions to Hospitals Treating Candida glabrata

Risk calculators and risk factors for Candida glabrata

Healthcare Provider Resources

Symptoms of Candida glabrata

Causes & Risk Factors for Candida glabrata

Diagnostic studies for Candida glabrata

Treatment of Candida glabrata

Continuing Medical Education (CME)

CME Programs on Candida glabrata

International

Candida glabrata en Espanol

Candida glabrata en Francais

Business

Candida glabrata in the Marketplace

Patents on Candida glabrata

Experimental / Informatics

List of terms related to Candida glabrata

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Candida glabrata is a haploid yeast of the genus Candida, previously known as Torulopsis glabrata. This species of yeast is non-dimorphic and there has been no observed mating activity. Until recently, C. glabrata was thought to be a primarily non-pathogenic organism. However, with the ever increasing population of immunocompromised individuals, trends have shown C. glabrata to be a highly opportunistic pathogen of the urogenital tract, and of the bloodstream (Candidemia). It is especially prevalent in HIV positive people, and the elderly.

There are two widely cited potential virulence factors that contribute to the pathogenicity of C. glabrata. The first is a series of adhesins coded by the EPA (epithelial adhesin) genes. These genes, located in the subtelomeric region, can respond to environmental cues that allow them to be expressed en masse so the organism can adhere to biotic and abiotic surfaces in microbial mats. This is also the suspected mechanism by which C. glabrata forms microbial "biofilms" on urinary catheters, and less commonly in-dwelling IV catheters. It also causes problems with dental devices, such as dentures. However, the formation of biofilms is very weak as compared to Candida albicans.

Another virulence factor that C. glabrata possesses is a wide-spectrum resistance to azole drugs, which are the most commonly prescribed antifungal (antimycotic) drugs. These drugs, including fluconazole and ketoconazole, are quite useless against C. glabrata. While some have said that the organism possesses an "innate" immunity to the drugs, it is more accurate to say that the organism possesses an evolved resistance to the drugs. It is still highly vulnerable to polyene drugs such as amphotericin B and nystatin, along with variable vulnerability to flucytosine and caspofungin.

References


Template:WS